Clinical Trial: The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional
Official Title: The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of volanesorsen given for 26 weeks in patients with Hypertriglyceridemia
Detailed Summary:
Sponsor: Ionis Pharmaceuticals, Inc.
Current Primary Outcome: The percent change in fasting triglycerides (TG) from baseline [ Time Frame: Baseline and 13 Weeks ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Ionis Pharmaceuticals, Inc.
Dates:
Date Received: November 20, 2014
Date Started: December 2014
Date Completion:
Last Updated: May 24, 2016
Last Verified: May 2016